McDermott + Bull Partner Ken Dropiewski talks with CRG Director Sabir Rassiwalla about how CRG is different from healthcare investment partners in the market.
Other News
RapidPulse Raises Additional Funding for Ischemic Stroke Therapies and Notes Promising Results
MIAMI, Sept. 13, 2022 /PRNewswire/ — RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced that it has raised an additional $10.5 million, bringing its cumulative financing to over $25 million. The financing was led by Syntheon and Santé Ventures who were joined by Epidarex Capital, Hatteras Venture Partners, and Broadview Ventures. RapidPulse plans […]
GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD) Trial also met its first key secondary endpoint, demonstrating higher diagnostic efficacy for [18F]flurpiridaz PET compared to SPECT Myocardial Perfusion Imaging (MPI) With a half-life roughly 12 times longer than currently approved […]
TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism
BIRMINGHAM, England, Sept. 13, 2022 /PRNewswire/ — Concept Medical announces the successful completion of the TRANSFORM 1 RCT (TReAtmeNt of Small coronary vessels: Randomized controlled trial FOR MagicTouch Sirolimus Coated Balloon). The Randomized Controlled Trial (RCT) was conceptualized with the aim of understanding how the treatment indications and applications of Drug Coated Balloon (DCB) in coronary artery disease […]
Boston Heart Diagnostics Launches Polygenic Risk Scores Empowering the Next Generation of Clinical Genomics
FRAMINGHAM, Mass., Sept. 12, 2022 /PRNewswire/ — Boston Heart Diagnostics is pleased to announce the availability of the Polygenic Risk Map™. These genetic tests leverage Polygenic Risk Scores (PRS) to provide physicians with a much more precise understanding of their patient’s absolute genetic risk of complex disease, allowing for the creation of early, personalized intervention […]
Prolifagen Therapeutics Appoints M. Alexander Shaw, PhD, as Chief Executive Officer
VILLANOVA, Pa., Sept. 13, 2022 /PRNewswire/ — Prolifagen Therapeutics, a biotech startup developing medicines for cardiac regeneration, has appointed M. Alexander Shaw, PhD, as Chief Executive Officer. In this role, Dr. Shaw will lead Prolifagen’s efforts in bringing new medicines to market to prevent development of heart failure in patients with large myocardial […]
Overland Park Regional Medical Center Extends Leadership in Robotic Treatment of Heart Rhythm Disorders with Plans for Second Stereotaxis System
ST. LOUIS, Sept. 13, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that Overland Park Regional Medical Center (OPRMC) is establishing its second robotic program for the treatment of heart rhythm disorders. OPRMC, a part of HCA Midwest […]
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2023 Financial Results
Nearing Completion of Patient Recruitment in FDA Pivotal Clinical Validation Study of MyoVista® Remains on Track for MyoVista® FDA De Novo Resubmission in Current Fiscal Year Southlake, Texas, Sept. 13, 2022 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company […]
THE SAGE GROUP Comments on National Peripheral Artery Disease (PAD) Awareness Month
BEAUFORT, S.C.–(BUSINESS WIRE)–According to THE SAGE GROUP, 21 million Americans suffer from PAD representing an economic burden of $283-$539 billion. “Twenty years ago we wrote that PAD was underestimated, underdiagnosed and undertreated,” stated Mary L. Yost, President. “Unfortunately, this is still true.” Reflecting on the current state of PAD and […]
TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery
BOSTON–(BUSINESS WIRE)–Abiomed (Nasdaq: ABMD) will highlight how Impella heart pumps help heart teams achieve more complete high-risk revascularization and heart recovery in the catheterization lab and operating room at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference, held in Boston from September 16 to 19. During the conference, physician-researchers will present clinical data […]
Recent
Hone Health Integrates Prenuvo Whole-Body MRI Scans to Power Preventive, Data-Driven Longevity Care
XCath Endovascular Robotic System Successfully Performs its First-In-Human Brain Aneurysm Procedures
First Clinical Investigation of a Gene Therapy (YAP101) to Induce Cardiac Regeneration to Treat Heart Failure Passes Initial Safety Hurdle
Popular
- No commented posts yet